Comparison of prevalence and types of mutations in lung cancers among black and white populations

JAMA Oncology

Volumn 3, Issue 6, 2017, Pages 801-809

  Campbell, Joshua D ^a,b   Lathan, Christopher ^a   Sholl, Lynette ^a   Ducar, Matthew ^c   Vega, Mikenah ^c   Sunkavalli, Ashwini ^c   Lin, Ling ^c   Hanna, Megan ^b   Schubert, Laura ^c   Thorner, Aaron ^c   Faris, Nicholas ^d   Williams, David R ^e,f   Osarogiagbon, Raymond U ^d   Van Hummelen, Paul ^c   Meyerson, Matthew ^a,b   MacConaill, Laura ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BAPTIST CANCER CENTER   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; AFRICAN AMERICAN; AGED; CAUCASIAN; CLINICAL TRIAL; COMPARATIVE STUDY; EPIDEMIOLOGY; ETHNOLOGY; FEMALE; GENE FUSION; GENETICS; HUMAN; HUMAN GENOME; LUNG TUMOR; MALE; MASSACHUSETTS; MULTICENTER STUDY; MUTATION; NON SMALL CELL LUNG CANCER; PREVALENCE; SMOKING; TENNESSEE;

ADENOCARCINOMA; AFRICAN AMERICANS; AGED; BOSTON; CARCINOMA, NON-SMALL-CELL LUNG; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FUSION; GENOME, HUMAN; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; PREVALENCE; SMOKING; TENNESSEE;

EID: 85025073386     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.6108     Document Type: Article

References (43)

1. Miller KD, Siegel RL, Lin C.C., et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271-289.
2. Howlader N, Noone AM, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2013, National Cancer Institute (basedon November 2015 SEER data submission, posted to the SEER web site, April 2016). http://seer.cancer.gov/csr/1975-2013/. Accessed December 12, 2016.
3. Geyer S. Social inequalities in the incidence and case fatality of cancers of the lung, the stomach, the bowels, and the breast. Cancer Causes Control. 2008; 19(9):965-974.
4. Albano JD, Ward E, Jemal A., et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst. 2007; 99(18):1384-1394.
5. Coughlin SS, Matthews-Juarez P, Juarez P.D., Melton CE, King M. Opportunities to address lung cancer disparities among African Americans. Cancer Med. 2014; 3(6):1467-1476.
6. Bach PB, Schrag D, Brawley O.W., Galaznik A., Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002; 287(16): 2106-2113.
7. Blackstock AW, Herndon JE II, Paskett ED, et al; Cancer and Leukemia Group B. Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Clin Oncol. 2006; 24(3):407-412.
8. Haiman CA, Stram DO, Wilkens L.R., et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med. 2006; 354(4):333-342.
9. Hanahan D, Weinberg RA Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.
10. Paez JG, Jänne PA, Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304 (5676):1497-1500.
11. Lynch TJ, Bell DW, Sordella R, et al Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21): 2129-2139.
12. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489 (7417):519-525.
13. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-550.
14. Imielinski M, Berger AH, Hammerman P.S., et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012; 150 (6):1107-1120.
15. Campbell JD, Alexandrov A, Kim J., et al; Cancer Genome Atlas Research Network. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016; 48(6):607-616.
16. Shigematsu H, Lin L, Takahashi T., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97(5):339-346.
17. Arrieta O, Cardona AF, Martin C, et al Updated Frequency of EGFR and KRAS Mutations in Non Small-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). J Thorac Oncol. 2015; 10(5): 838-843.
18. Fong T, Morgensztern D, Govindan R. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. J Thorac Oncol. 2008; 3 (3):303-310.
19. Blackhall F, Ranson M, Thatcher N. Where next for gefitinib in patients with lung cancer? Lancet Oncol. 2006; 7(6):499-507.
20. Yang CH. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. Lung Cancer. 2008; 60(suppl 2):S23-S30.
21. Yang SH, Mechanic LE, Yang P, et al Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res. 2005; 11(6):2106-2110.
22. Bauml J, Mick R, Zhang Y., et al. Frequency of EGFR and KRAS mutations inpatients with non small cell lung cancer by racial background: do disparities exist? Lung Cancer. 2013; 81(3):347-353.
23. Bollig-Fischer A., Chen W, Gadgeel S.M., et al. Racial diversity of actionable mutations in non-small cell lung cancer. J Thorac Oncol. 2015; 10 (2):250-255.
24. Leidner RS, Fu P, Clifford B., et al. Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. J Clin Oncol. 2009; 27(33):5620-5626.
25. Araujo LH, Lammers PE, Matthews-Smith V, et al. Somatic mutation spectrum of non-small-cell lung cancer in African americans: a pooled analysis. J Thorac Oncol. 2015; 10(10):1430-1436.
26. Yamaguchi N, Vanderlaan PA, Folch E, et al Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. Lung Cancer. 2013; 82(1):31-37.
27. Reinersman JM, Johnson ML, Riely G.J., et al. Frequency of EGFR and KRAS mutations inlung adenocarcinomas in African Americans. J Thorac Oncol. 2011; 6(1):28-31.
28. Cote ML, Haddad R, Edwards D.J., et al. Frequency and typeofepidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. J Thorac Oncol. 2011; 6 (3):627-630.
29. Wagle N, Berger MF, Davis M.J., et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012; 2(1):82-93.
30. DePristo MA, Banks E, Poplin R., et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011; 43(5):491-498.
31. Cibulskis K, Lawrence MS, Carter S.L., et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31(3):213-219.
32. Ramos AH, Lichtenstein L, Gupta M., et al. Oncotator: cancer variant annotation tool. Hum Mutat. 2015; 36(4):E2423-E2429.
33. Abo RP, Ducar M, Garcia E.P., et al. BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic Acids Res. 2014; 43(3):e19.
34. Price AL, Patterson NJ, Plenge R.M., Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006; 38(8): 904-909.
35. Abraham G, Inouye M. Fast principal component analysis of large-scale genome-wide data. PLoS One. 2014; 9(4):e93766.
36. Toyooka S, Matsuo K, Shigematsu H., et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res. 2007; 13(19):5763-5768.
37. Alexandrov LB, Nik-Zainal S, Wedge D.C., Campbell PJ, Stratton MR. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 2013; 3(1):246-259.
38. Alexandrov LB, Nik-Zainal S, Wedge D.C., et al; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain. Signatures of mutational processes in human cancer. Nature. 2013; 500(7463):415-421.
39. Oxnard GR, Binder A, Jänne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol. 2013; 31(8):1097-1104.
40. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011; 12(2): 175-180.
41. Pao W, Hutchinson KE Chipping away atthe lung cancer genome. Nat Med. 2012; 18(3):349-351.
42. Roberts SA, Lawrence MS, Klimczak L.J., et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013; 45(9):970-976.
43. Hebbring SJ, Adjei AA, Baer J.L., et al. Human SULT1A1 gene: copy number differences and functional implications. Hum Mol Genet. 2007; 16 (5):463-470.